

Opioid Induced Constipation Treatment Market - 2025-2033

<https://marketpublishers.com/r/O3A2AF4A06DEEN.html>

Date: April 2026

Pages: 217

Price: US\$ 2,999.00 (Single User License)

ID: O3A2AF4A06DEEN

Abstracts

The Opioid Induced Constipation Treatment Market was valued at US\$ 1,241.90 million in 2025 and is anticipated to reach US\$ 1,835.00 million by 2033, at a CAGR of 0.05 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Opioid Induced Constipation Treatment Market.

This report delivers a comprehensive overview of the Opioid Induced Constipation Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Opioid Induced Constipation Treatment Market. The Opioid Induced Constipation Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Opioid Induced Constipation Treatment Market Scope:

By Drug Class

Mu-Opioid Receptor Antagonists

Chloride Channel Activators

By Route of Administration

Oral

Parenteral

By Distribution Channel

Hospital pharmacies

Online pharmacies

Retail pharmacies

Key Players

Takeda Pharmaceuticals Company Ltd

AstraZeneca

Shionogi & Company, Limited

Bausch Health Companies Inc(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Opioid Induced Constipation Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Opioid Induced Constipation Treatment Market. The Opioid Induced Constipation Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and

revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising Prevalence of Opioid-Induced Constipation
 - 4.1.2. Restraints
 - 4.1.2.1. Low Diagnosis Rate
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Regulatory Analysis
 - 5.3.1. Demand-Supply Spectrum
 - 5.3.2. Government Initiatives Related to the Market During Pandemic
 - 5.3.3. Manufacturer's Strategic Initiatives
 - 5.3.4. Conclusion

6. BY DRUG CLASS

- 6.1. Introduction
 - 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
 - 6.1.2. Market Attractiveness Index, By Drug Class Segment
- 6.2. Mu-Opioid Receptor Antagonists
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis, US\$ Million, 2022-2030 and Y-o-Y Growth Analysis (%),

2022-2030

6.2.2.1. Naldemedine

6.2.2.2. Naloxegol

6.2.2.3. Methylnaltrexone

6.3. Chloride Channel Activators

6.3.1. Lubiprostone

7. BY ROUTE OF ADMINISTRATION

7.1. Introduction

7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment

7.1.2. Market Attractiveness Index, By Route of Administration Segment

7.2. Oral

7.2.1. Introduction

7.2.2. Market Size Analysis, US\$ Million, 2022-2030 and Y-o-Y Growth Analysis (%), 2022-2030

7.3. Parenteral

8. BY DISTRIBUTION CHANNEL

8.1. Introduction

8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment

8.1.2. Market Attractiveness Index, By Distribution Channel Segment

8.2. Hospital pharmacies

8.2.1. Introduction

8.2.2. Market Size Analysis, US\$ Million, 2022-2030 and Y-o-Y Growth Analysis (%), 2022-2030

8.3. Online pharmacies

8.4. Retail pharmacies

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis, US\$ Million, 2022-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material
- 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 9.2.7.1. The U.S.
 - 9.2.7.2. Canada
 - 9.2.7.3. Mexico
- 9.3. Europe
 - 9.3.1. Introduction
 - 9.3.2. Key Region-Specific Dynamics
 - 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
 - 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material
 - 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
 - 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
 - 9.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 9.3.7.1. Germany
 - 9.3.7.2. The U.K.
 - 9.3.7.3. France
 - 9.3.7.4. Italy
 - 9.3.7.5. Spain
 - 9.3.7.6. Rest of Europe
- 9.4. South America
 - 9.4.1. Introduction
 - 9.4.2. Key Region-Specific Dynamics
 - 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
 - 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material
 - 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
 - 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
 - 9.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 9.4.7.1. Brazil
 - 9.4.7.2. Argentina
 - 9.4.7.3. Rest of South America
- 9.5. Asia Pacific
 - 9.5.1. Introduction
 - 9.5.2. Key Region-Specific Dynamics
 - 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 9.5.7.1. China
 - 9.5.7.2. India
 - 9.5.7.3. Japan
 - 9.5.7.4. Australia
 - 9.5.7.5. Rest of Asia Pacific

9.6. Middle East and Africa

- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. COMPETITIVE LANDSCAPE

- 10.1. Key Developments and Strategies
- 10.2. Company Share Analysis
- 10.3. Product Benchmarking

11. COMPANY PROFILES

- 11.1. Takeda Pharmaceuticals Company Ltd
 - 11.1.1. Company Overview
 - 11.1.2. Product Portfolio and Description
 - 11.1.3. Key Highlights
 - 11.1.4. Financial Overview
- 11.2. AstraZeneca
- 11.3. Shionogi & Company, Limited
- 11.4. Bausch Health Companies Inc(*LIST NOT EXHAUSTIVE)

12. DATAM INTELLIGENCE

- 12.1. Appendix
- 12.2. About Us and Services
- 12.3. Contact Us

I would like to order

Product name: Opioid Induced Constipation Treatment Market - 2025-2033

Product link: <https://marketpublishers.com/r/O3A2AF4A06DEEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O3A2AF4A06DEEN.html>